Recurrences can occur in up to 30% of surgically managed patients with localized renal cell carcinoma. Existing uro-oncological guidelines differ in recommendations of surveillance protocols and identification of patients at risk. A recent study shows that the existence of differing guidelines results in inadequate harms, cancer control and costs.
Refers to Lobo, J. et al. Comparison of renal cell carcinoma surveillance guidelines: competing tradeoffs. J. Urol.http://dx.doi.org/10.1016/j.juro.2015.12.094 (2016)